We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.06 | -0.14% | 43.93 | 44.62 | 43.78 | 44.16 | 9,127,652 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
Shares of pharmaceutical company Bristol-Myers Squibb Co. (BMY) are falling in Wednesday's late trading session after the company said a trial evaluating Opdivo plus chemotherapy in certain cancer patients didn't meet its pre-specified primary endpoint.
At 5:04 p.m. EDT, Bristol-Myers Squibb shares had lost 4.7% to trade at $41.20. After-hours volume topped 357,000 shares.
The company's shares closed the day's regular trading session with a 0.42% gain at $43.23.
After the bell, the company said Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo, or nivolumab, with low-dose Yervoy, or ipilimumab, in certain cancer patients met the co-primary endpoint of overall survival.
Part 2 of the CheckMate -227 trial, evaluating Opdivo plus chemotherapy, didn't meet the pre-specified primary endpoint.
The company also said the time for its second-quarter earnings call has been rescheduled to 8:30 a.m. EDT on July 25.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 24, 2019 17:30 ET (21:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
